The present disclosure relates generally to the use of methazolamide in the treatment or prevention of liver diseases, including elevated liver lipid levels and NAFLD, as well as its use in decreasing serum ALT levels. The disclosure also relates to combinations and compositions comprising methazolamide and an anti-diabetic agent, such as metformin.
